Answers are grounded in this paper and cite their sources.
Importance The optimal atropine concentration for myopia control in children with coexisting intermittent exotropia (IXT) remains uncertain. Objective To compare the efficacy and safety of 0.01%, 0.02%, and 0.04% atropine eye drops in children with myopia and IXT. Design, Setting, and Participants This single-center, double-masked, 3-arm randomized clinical trial was conducted from September 2023 to March 2026. Children aged 6 to 12 years with basic-type IXT and myopia (cycloplegic spherical equivalent [SE], −0.50 to −6.00 diopters [D]) were enrolled. Data analysis was conducted from March 2026 to July 2026. Interventions Participants were randomized 1:1:1 to 0.01%, 0.02%, or 0.04% atropine eye drops nightly in both eyes. Main Outcomes and Measures The primary outcome was 12-month change in cycloplegic SE. Secondary outcomes included changes in axial length (AL), exotropia conditions, binocular vision, and ocular safety parameters. Results Among 264 randomized children (mean [SD] age, 8.4 [1.5] years; 130 female [49.2%]), 224 (84.8%) completed the 12-month assessment. Mean (SD) SE changes were −0.43 (0.50) D, −0.35 (0.51) D, and −0.18 (0.60) D with 0.01%, 0.02%, and 0.04% atropine, respectively (overall P = .001). Compared with 0.01% and 0.02% atropine, 0.04% atropine was associated with less SE progression (vs 0.01%: difference, 0.24 D; 95% CI, 0.11-0.37 D; P < .001; vs 0.02%: difference, 0.16 D; 95% CI, 0.04-0.29 D; P = .02). Mean (SD) AL changes were 0.31 (0.25) mm, 0.25 (0.23) mm, and 0.15 (0.29) mm, respectively (overall P < .001); corresponding differences for 0.04% vs 0.01% and 0.02% were −0.16 mm (95% CI, −0.22 to −0.10 mm; P < .001) and −0.10 mm (95% CI, −0.16 to −0.04 mm; P < .001). Mean (SD) near exodeviation decreased by 3.46 (5.76) prism diopters (PD), 4.84 (8.05) PD, and 6.13 (7.11) PD, respectively (overall P = .04); the reduction was greater with 0.04% vs 0.01% atropine (difference, −2.68 PD; 95% CI, −4.78 to −0.57 PD; P = .008). Study drug–related photophobia occurred in 8 (9.1%), 9 (10.2%), and 19 participants (21.6%) in the 0.01%, 0.02%, and 0.04% atropine groups, respectively; no participant discontinued treatment because of photophobia. Conclusions and Relevance In the AMIXT2 randomized clinical trial among children with myopia and IXT, 0.04% atropine eye drops were associated with less myopia progression and axial elongation over 12 months than 0.01% or 0.02% atropine eye drops. Higher concentrations were associated with greater reductions in near magnitude of exodeviation, which warrant further investigation. Trial Registration chictr.org.cn Identifier: ChiCTR2300075312
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: